Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.

PATIENTS AND METHODS: This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allogeneic stem cell transplantation (allo-HCT). RESULTS: We included 428...

Descripción completa

Detalles Bibliográficos
Autores: Piñana JL, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen JJ, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual MJ, Yeshurun M, Finke J, Groll AH, Shaw PJ, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p17168
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17168
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
allogeneic hematopoietic stem cell transplantation
community-acquired respiratory virus
human Coronavirus
human metapneumovirus
immunocompromised
immunodeficiency score index
multiplex PCR assay
paramyxovirus
upper and lower respiratory tract disease
id ES_f9b9cd39e44b5d6e32ed6dcb7823c8c8
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p17168
network_acronym_str ES
network_name_str España
repository_id_str
spelling Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.Piñana JLTridello GXhaard AWendel LMontoro JVazquez LHeras ILjungman PMikulska MSalmenniemi UPerez AKröger NCornelissen JJSala EMartino RGeurten CByrne JMaertens JKerre TMartin MPascual MJYeshurun MFinke JGroll AHShaw PJBlijlevens NArcese WGanser ASuarez-Lledo MAlzahrani MChoi GForcade EPaviglianiti ASolano CWachowiak JZuckerman TBader PClausen JMayer JSchroyens WMetafuni EKnelange NAverbuch Dde la Camara RSARS-CoV-2allogeneic hematopoietic stem cell transplantationcommunity-acquired respiratory virushuman Coronavirushuman metapneumovirusimmunocompromisedimmunodeficiency score indexmultiplex PCR assayparamyxovirusupper and lower respiratory tract diseasePATIENTS AND METHODS: This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allogeneic stem cell transplantation (allo-HCT). RESULTS: We included 428 allo-HCT recipients who developed 438 hMPV infection episodes between January 2012 and January 2019. Most recipients were adults (93%). hMPV infections were diagnosed at a median of 373 days after allo-HCT. The infections were categorized as upper respiratory tract disease (URTD) or lower respiratory tract disease (LRTD), with 60% and 40% of cases, respectively. Patients with hMPV LRTD experienced the infection earlier in the transplant course and had higher rates of lymphopenia, neutropenia, corticosteroid use, and ribavirin therapy. Multivariate analysis identified lymphopenia and corticosteroid use (>30 mg/d) as independent risk factors for LRTD occurrence. The overall mortality at day 30 after hMPV detection was 2% for URTD, 12% for possible LRTD, and 21% for proven LRTD. Lymphopenia was the only independent risk factor associated with day 30 mortality in LRTD cases. CONCLUSIONS: These findings highlight the significance of lymphopenia and corticosteroid use in the development and severity of hMPV infections after allo-HCT, with lymphopenia being a predictor of higher mortality in LRTD cases.OXFORD UNIV PRESS INC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17168JOURNAL OF INFECTIOUS DISEASESISSN: 00221899ISSNe: 15376613reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p171682026-06-14T12:41:47Z
dc.title.none.fl_str_mv Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
title Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
spellingShingle Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
Piñana JL
SARS-CoV-2
allogeneic hematopoietic stem cell transplantation
community-acquired respiratory virus
human Coronavirus
human metapneumovirus
immunocompromised
immunodeficiency score index
multiplex PCR assay
paramyxovirus
upper and lower respiratory tract disease
title_short Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
title_full Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
title_fullStr Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
title_full_unstemmed Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
title_sort Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.
dc.creator.none.fl_str_mv Piñana JL
Tridello G
Xhaard A
Wendel L
Montoro J
Vazquez L
Heras I
Ljungman P
Mikulska M
Salmenniemi U
Perez A
Kröger N
Cornelissen JJ
Sala E
Martino R
Geurten C
Byrne J
Maertens J
Kerre T
Martin M
Pascual MJ
Yeshurun M
Finke J
Groll AH
Shaw PJ
Blijlevens N
Arcese W
Ganser A
Suarez-Lledo M
Alzahrani M
Choi G
Forcade E
Paviglianiti A
Solano C
Wachowiak J
Zuckerman T
Bader P
Clausen J
Mayer J
Schroyens W
Metafuni E
Knelange N
Averbuch D
de la Camara R
author Piñana JL
author_facet Piñana JL
Tridello G
Xhaard A
Wendel L
Montoro J
Vazquez L
Heras I
Ljungman P
Mikulska M
Salmenniemi U
Perez A
Kröger N
Cornelissen JJ
Sala E
Martino R
Geurten C
Byrne J
Maertens J
Kerre T
Martin M
Pascual MJ
Yeshurun M
Finke J
Groll AH
Shaw PJ
Blijlevens N
Arcese W
Ganser A
Suarez-Lledo M
Alzahrani M
Choi G
Forcade E
Paviglianiti A
Solano C
Wachowiak J
Zuckerman T
Bader P
Clausen J
Mayer J
Schroyens W
Metafuni E
Knelange N
Averbuch D
de la Camara R
author_role author
author2 Tridello G
Xhaard A
Wendel L
Montoro J
Vazquez L
Heras I
Ljungman P
Mikulska M
Salmenniemi U
Perez A
Kröger N
Cornelissen JJ
Sala E
Martino R
Geurten C
Byrne J
Maertens J
Kerre T
Martin M
Pascual MJ
Yeshurun M
Finke J
Groll AH
Shaw PJ
Blijlevens N
Arcese W
Ganser A
Suarez-Lledo M
Alzahrani M
Choi G
Forcade E
Paviglianiti A
Solano C
Wachowiak J
Zuckerman T
Bader P
Clausen J
Mayer J
Schroyens W
Metafuni E
Knelange N
Averbuch D
de la Camara R
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SARS-CoV-2
allogeneic hematopoietic stem cell transplantation
community-acquired respiratory virus
human Coronavirus
human metapneumovirus
immunocompromised
immunodeficiency score index
multiplex PCR assay
paramyxovirus
upper and lower respiratory tract disease
topic SARS-CoV-2
allogeneic hematopoietic stem cell transplantation
community-acquired respiratory virus
human Coronavirus
human metapneumovirus
immunocompromised
immunodeficiency score index
multiplex PCR assay
paramyxovirus
upper and lower respiratory tract disease
description PATIENTS AND METHODS: This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allogeneic stem cell transplantation (allo-HCT). RESULTS: We included 428 allo-HCT recipients who developed 438 hMPV infection episodes between January 2012 and January 2019. Most recipients were adults (93%). hMPV infections were diagnosed at a median of 373 days after allo-HCT. The infections were categorized as upper respiratory tract disease (URTD) or lower respiratory tract disease (LRTD), with 60% and 40% of cases, respectively. Patients with hMPV LRTD experienced the infection earlier in the transplant course and had higher rates of lymphopenia, neutropenia, corticosteroid use, and ribavirin therapy. Multivariate analysis identified lymphopenia and corticosteroid use (>30 mg/d) as independent risk factors for LRTD occurrence. The overall mortality at day 30 after hMPV detection was 2% for URTD, 12% for possible LRTD, and 21% for proven LRTD. Lymphopenia was the only independent risk factor associated with day 30 mortality in LRTD cases. CONCLUSIONS: These findings highlight the significance of lymphopenia and corticosteroid use in the development and severity of hMPV infections after allo-HCT, with lymphopenia being a predictor of higher mortality in LRTD cases.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17168
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17168
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS INC
publisher.none.fl_str_mv OXFORD UNIV PRESS INC
dc.source.none.fl_str_mv JOURNAL OF INFECTIOUS DISEASES
ISSN: 00221899
ISSNe: 15376613
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425121016414208
score 15,812429

Similares en LA Referencia